GSK plc (LSE/NYSE: GSK)は、呼吸器合胞体ウイルス(RSV)ワクチンAREXVYの使用対象を、重症RSV感染リスクの高い50〜59歳の成人に拡大する承認を欧州委員会から得た。これまでは60歳以上の成人のみが対象であったが、RSVの流行シーズン直前にこの適応拡大が実現した ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines ...

GSK’s Arexvy now recommended for adults 50-59 at risk Open in App Get 45% Off Sign In Free Sign Up ...

GSK’s Arexvy now recommended for adults 50-59 at risk ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...